Daiichi Sankyo Subsidiary Submits NDA For Alzheimer's Disease Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo subsidiary Asubio Pharma submitted an NDA for SUN Y7017 (memantine) for Alzheimer's disease in Japan. An N-methyl-D-aspartate receptor antagonist developed by German firm Merz Pharmaceuticals, memantine was approved by the European Medicines Agency in 2002 and by U.S. FDA in 2003.The drug is now marketed in over 60 countries. Developed by Asubio in Japan, memantine will be marketed by Daiichi Sankyo upon approval. (Click here for more - Japanese language
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.